CVS Health's Caremark subsidiary has settled a long-running antitrust case with the FTC, agreeing to significant changes in its rebate and pricing practices. This settlement aims to lower prescription drug costs and increase transparency, potentially saving consumers billions over the next decade.
CVS Health's Caremark subsidiary has reached a settlement with the FTC, resolving a significant antitrust case that alleged rebate-driven practices artificially inflated drug prices. This agreement mandates substantial changes to Caremark's business model, including offering plan sponsors options for direct rebate pass-through to consumers and increasing transparency. While the settlement removes a legal overhang for CVS, the required changes could impact its PBM revenue model in the long term. For competitors like Cigna's Express Scripts (which already settled) and UnitedHealth's Optum (still under review), this sets a precedent, suggesting similar regulatory pressures and potential future settlements. Short-term, CVS shares saw a slight dip, reflecting uncertainty around the financial implications of these operational overhauls, but the long-term impact could be a more competitive and transparent PBM market.